Dario contracts with new employer for cardiometabolic solution

Demand for dario's integrated cardiometabolic solution continues to grow as employers grappling with the surge in glp-1 medication utilization search for proven ways to change health behaviors new york , nov. 27, 2023 /prnewswire/ -- dariohealth corp. (nasdaq: drio) ("dario" or the "company"), a leader in the global digital health market, announced today a new contract to provide its cardiometabolic solution to an employer (the "employer") beginning in january 2024.     the employer, a national financial and business services company, selected dario to improve the cardiometabolic health of its population with an integrated solution for diabetes, pre-diabetes, weight management and hypertension along with tailored support for employees taking a glp-1, or anti-obesity, medications.
DRIO Ratings Summary
DRIO Quant Ranking